Organon India has established a co-marketing arrangement with Glaxo SmithKline Pharmaceuticals India for two of its oral contraceptive pills - Femilon and Cerazette. This arrangement is valid for a period of ten years.

Organon worldwide has been an innovator and leading player in the field of contraception for over three decades. In India, Organon has a significant market share in the oral contraceptive segment. With this arrangement, Organon India seeks to further develop the contraceptive market, the release stated here.

B N Chakraborty, managing director, Organon India said, "Glaxo Smithkline with its large marketing network will strengthen our efforts to bring innovative products to the Indian market. Together, we will build a stronger awareness about modern methods of contraception and thereby help a large segment of doctors and women make an informed choice with regard to the latter's contraceptive needs."

Femilon, the lowest-dose oral contraceptive is indicated for women who want to use the lightest Pill. Cerazette, India's first Estrogen-Free Pill (EFP) is particularly suitable for nursing mothers and estrogen-sensitive women.